Francesca Sperandi

机构：Azienda USL di Bologna, Istituti di Ricovero e Cura a Carattere Scientifico · ORCID：0000-0002-1581-3456

发表论文 102 篇 · 总被引 1001 次 · h-index 19

代表论文

• Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis (2025 · The Lancet Oncology · 被引 44)
• Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors (2024 · Annals of Oncology · 被引 27)
• STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status (2024 · Lung Cancer · 被引 20)
• Efficacy and Safety of TROP-2-Targeting Antibody–Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data (2025 · Cancers · 被引 8)
• Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy (2024 · Cancer Immunology Immunotherapy · 被引 6)
• Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% (2025 · ESMO Open · 被引 4)